Peptides and small molecules may play an important role in immuno-oncology because they may bind to multiple immune checkpoint proteins via rational design, opening opportunity for a new generation of novel PD-1/PD-L1 inhibitors.
No takes yet. Share an insight, caveat, or question.
Geng et al. (2018) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: